Mitoxantrone, fluorouracil, and L-folinic acid in anthracycline-pretreated metastatic breast cancer patients

Breast Cancer Research and Treatment

Volumn 45, Issue 3, 1997, Pages 205-210

  Bascioni, Romeo ^a,d   Giorgi, Francesca ^b   Silva, Rosa Rita ^b   Acito, Luigi ^a   Giustini, Lucio ^a   De Signoribus, Giorgio ^b   Giuliodori, Luciano ^b   Testa, Enrica ^c  

^a City Hospital of Fermo   (Italy)

^b Medical Oncology   (Italy)

^c Oncology Unit   (Italy)

^d Ospedale 'Murri'   (Italy)

Author keywords

Breast cancer; Chemotherapy; Fluorouracil; Folinic acid; Mitoxantrone

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; FLUOROURACIL; FOLINIC ACID; MITOXANTRONE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BLOOD TOXICITY; BREAST CANCER; CARDIOTOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DRUG EFFICACY; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; METASTASIS; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; STOMATITIS; THROMBOCYTOPENIA;

ADULT; AGED; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; BREAST NEOPLASMS, MALE; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, NEOPLASM; FEMALE; FLUOROURACIL; HUMANS; LEUCOVORIN; MALE; MIDDLE AGED; MITOXANTRONE; NEOPLASM METASTASIS;

EID: 0030661718     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1005856028736     Document Type: Article

References (16)

1. Henderson IC, Harris JR: Principles in the management of metastatic disease. In: Harris JR, Hellman S, Henderson IC, Kinne D (eds) Breast Disease (ed. 2). Lippincott. Philadelphia, PA, 1991, pp 627
2. Swain SM, Lippman ME, Egan EF, Drake JC, Steinberg SM, Allegra CJ: Fluorouracil and high-dose leucovorin in previously treated patients with metastatic breast cancer. J Clin Oncol 7: 890-899, 1989
3. Doroshow JH, Leong L, Margolin K, Flanagan B, Goldberg D, Bertrand M, Akman S, Carr B, Odujinrin O, Newman E: Refractory metastatic breast cancer: Salvage therapy with fluorouracil and high-dose continuous infusion leucovorin calcium. J Clin Oncol 7: 439-444, 1989
4. Hainsworth JD, Andrews MB, Johnson DH, Greco FA: Mitoxantrone, fluorouracil and high-dose leucovorin: An effective, well-tolerated regimen for metastatic breast cancer. J Clin Oncol 9: 1731-1736, 1991
5. Jones SE, Mennel RG, Brooks B, Westrik MA, Allison MA, Paulson RS, Tilmann K, Rea B: Phase 11 study of Mitoxantrone, leucovorin, and infusional fluorouracil for treatment of metastatic breast cancer. J Clin Oncol 9: 1736-1739, 1991
6. Wils JA: Mitoxantrone, leucovorin and high-dose infusional 5-fluorouracil: an effective and well tolerated regimen for the treatment of advanced breast cancer. Eur J Cancer 29A: 2106-2108, 1993
7. Despax R, Gratet A: Combination chemotherapy of metastatic breast cancer with high-dose leucovorin, 5FU and mitoxantrone: Pilot study with escalating doses. Proc Am Soc Clin Oncol 10: 63, 1991 (abstr 127)
8. Swain S, Honig S, Johnson K, Egan E, Walton L, Pickle L, Tefft M, George M: A mitoxantrone, 5-fluorouracil and high-dose leucovorin regimen as treatment for patients with metastatic breast cancer. Proc Am Soc Clin Oncol 10: 54, 1991 (abstr 89)
9. Miller AB, Hoogstraten B, Staquet M, Winkler A: Reporting results of cancer treatment. Cancer 47: 207-214, 1981
10. Porkka K, Blomqvist C, Rissanen P, Elomaa I, Pyrhönen S: Salvage therapies in women who failed to respond to first-line treatment with fluorouracil, epirubicin and cyclophosphamide for advanced breast cancer. J Clin Oncol 12: 1639-1647, 1994
11. Henderson IC, Allegra JC, Woodcock T, Wolff S, Bryan S, Cartwright K, Dukart G, Henry D: Randomized clinical trial comparing mitoxantrone with doxorubicin in previously treated patients with metastatic breast cancer. J Clin Oncol 7: 560-571, 1989
12. Jolivet J, Belanger K, Yelle L, Guevin R, Potvin M, Wilson J, Rudinskas L, Latreille J, Dionne J, Gagne L, Aioub J: The importance of dose scheduling with mitoxantrone, 5-fluorouracil and leucovorin in metastatic breast cancer. Eur J Cancer 30A: 626-628, 1994
13. Zaniboni A, Meriggi F, Arcangeli G, Marpicati P, Montini E, Simoncini E, Marini G: L-folinic acid and fluorouracil in the treatment of advanced breast cancer: A phase II study. Ann Oncol 2: 41-43, 1993 (Suppl 2)
14. Seidman AD, Reichman BS, Crown JP, Yao TJ, Currie V, Hakes TB, Hudis CA, Gilewski TA, Baselga J, Forsythe P, Lepore J, Marks L, Fain K, Souhrada M, Onetto N, Arbuck S, Norton L: Paclitaxel as second and subsequent therapy for metastatic breast cancer: activity independent of prior anthracycline response. J Clin Oncol 13: 1152-1159, 1995
15. Wilson WH, Berg SL, Bryant G, Wittes RE, Bates S, Foio A, Steinberg SM, Goldspiel BR, Herdt J, O'Shaughnessy J, Balis FM, Chabner BA: Paclitaxel in doxorubicin-refractory or mitoxantrone-refractory breast cancer: A Phase I-II trial of 96-hour infusion. J Clin Oncol 12: 1621-1629, 1994
16. Hainsworth JD, Jones SE, Mennel RG, Blum JL, Greco FA: Paclitaxel with mitoxantrone, fluorouracil and high dose leucovorin in the treatment of metastatic breast cancer: A phase II trial. J Clin Oncol 14: 1611-1616, 1996